- Teerlink, John;
- McMurray, J;
- Packer, M;
- Desai, A;
- Gong, J;
- Greenlaw, N;
- Lefkowitz, M;
- Rizkala, A;
- Shi, V;
- Rouleau, J;
- Solomon, S
© The Author 2014.Aims Although active-controlled trials with renin-angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compa